Martin Stefanic
Martin Stefanic, Patient Safety Therapeutic Area Head for Oncology, discusses his move to Patient Safety.
Search
BI X colleague about working with purpose
Ding works on an app that gives patients remote access to stroke rehabilitation via their mobile phones and tablets
Uncommon_Mutations_Database
New database of published clinical outcomes from patients with uncommon EGFR mutations in advanced NSCLC treated with afatinib is available for global clinician use
Saving Stroke Patients around the world
Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. Over 15 million people worldwide suffer a stroke every year.
new_analysis_nintedanib_SSc_ILD
Interim analysis results support long term treatment with nintedanib in SSc-ILD patients
U.S. FDA grants priority review for spesolimab in GPP
U.S. FDA grants priority review for spesolimab in the treatment of patients with generalized pustular psoriasis
GioTag Final Data
Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients
Boehringer Ingelheim reaches more patients than ever, innovation drives growth
Boehringer Ingelheim reports a strong performance in 2022.
Patient Documentary
People with type 2 diabetes are two to four times more likely to develop heart disease compared with people without diabetes
RE-LY-trial-publication-10-year-anniversary
Boehringer Ingelheim recognises the contribution made in the decade since the RE-LY® trial publication by patients, HCPs and researchers
InPedILD_trial_enrollment
First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents
FDA-approves-nintedanib-in-SSc-ILD
FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
Cystic Fibrosis Genetherapy Development Option Excercise
Boehringer Ingelheim and Partners Accelerate BI 3720931 Gene Therapy as long-lasting therapeutic option for patients with cystic fibrosis
Trailr2-cdh17-antibody-phase1-trial
Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers
Collaboration Boehringer Ingelheim Veeva technology
Boehringer Ingelheim selects Veeva Development Cloud worldwide to bring innovative therapies to patients faster
emperor-preserved-chmp-positive-opinion
CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
PCI with stenting animation
A short animation explaining what Percutaneous Coronary Intervention (PCI) with stenting is, why it is used in AF patients and the unmet need in current treatment strategies
New spesolimab data show significant improvement in GPP flares
New spesolimab data show significant improvement in GPP flares
Sales consultant about working with purpose
Bok talks about how he found purpose in his career. After his father was diagnosed with cancer, he decided to work as an oncology sales consultant.
Patient safety your career opportunity
Discover a role in Patient Safety
Biotherapeutics Discovery
We are applying our deep understanding of disease biology to design a diverse range of novel modalities that are the foundation for life-changing biotherapeutics for patients.
From social worker to joining the pharmaceutical industry
Patient centricity: How Miyuki Ono contributes to our diverse workforce with her experience as a social worker and helps patients in Japan
Breaking prejudice in lung cancer
At Boehringer Ingelheim, addressing patient needs and fighting stigma in lung cancer care are two focus topics of the patient engagement team in oncology.
Brightline-1 trial launch in rare sarcoma
Mehdi Lahmar discusses “Brightline-1”, and our commitment to patients with Dedifferentiated Liposarcoma (DDLPS).
Our Innovation Strategy
A deep understanding of disease, identifying relevant mechanisms and choosing therapeutic modalities to address them is the core of our innovation strategy